



PRESS RELEASE

DuChemBio and Nihon Medi-Physics sign Joint Development and Distribution Agreement to Develop and Commercialize FACBC

DuChemBio, Ltd. (DCB), a leading radio-pharmaceutical company in Korea, and Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company in Japan, today announced that they have entered into an exclusive agreement to develop, register and commercialize anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (FACBC) in Korea. FACBC is an agent for positron emission tomography (PET) imaging of recurrent prostate cancer.

FACBC has been granted marketing authorizations by the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in EU for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence. Prostate cancer patients whose blood test for prostate-specific antigen (PSA) indicate that the cancer may have returned after the initial treatment, such as prostatectomy, usually undergo conventional imaging tests (e.g. CT, MRI, bone scintigraphy). However, the chances to find recurrent cancer lesions in such patients using conventional imaging are relatively low. FACBC-enhanced PET-CT imaging is a proven diagnostic tool for highly optimal management of patients with suspected prostate cancer recurrence in the US and EU.

DCB and NMP will work closely to develop and launch FACBC in Korea and make it available throughout the market. NMP has the worldwide rights to FACBC, and under this agreement, DCB will be the exclusive supplier of FACBC in Korea.

“This contract for joint development and commercialization of FACBC is all the more meaningful in that DuChemBio gains the opportunity to enter the prostate cancer market as a first mover in Korea. As a result, the two leading companies made an important first step in building a strategic collaboration to develop and launch innovative PET tracers to serve Nuclear Medicine customers and patients in the Asia Pacific region. Based on this first step, I expect that both companies can pursue further projects in the development, manufacturing and commercialization of new radiopharmaceutical products and will expand their business relationship soon” said Mr. Kim Jongwoo, President and CEO of DuChemBio.

“We have been operating our business to contribute to healthcare in Japan, but from now on our commitment should be expanded to development of healthcare in Asia. In order to start our business operation in Asian countries, it is quite encouraging for us to enter into partnership with DuChemBio, which has many achievements as a radiopharmaceutical company in Korea. With the availability of FACBC PET imaging, we look forward to contributing to healthcare in Korea through close cooperation between us.” said Mr. Hisashi Shimoda, President of Nihon Medi-Physics Co. Ltd.

About DuChemBio

Established in 2002, DuChemBio is the largest radiopharmaceutical firm and the undisputed leader in the field of oncology and neurology PET imaging tracers in Korea. As a pioneer of a fully



integrated business model, DuChemBio, develops, obtains regulatory approvals, manufactures, sells and promotes PET radiopharmaceutical solutions to Nuclear Medicine and referring physicians and hence contributes to an early and most accurate diagnosis of life-threatening diseases. DuChemBio's broad portfolio includes FDG for cancer diagnosis, FP-CIT for the diagnosis of Parkinson's disease and Neuraceq (FBB) for Imaging of patients suspected to suffer from Alzheimer's disease.

About BGM Associates

The signing of the DCB – NMP Agreement has been facilitated by BGM Associates GmbH, a Berlin-based strategy and transaction advisory firm with an industry focus on healthcare and life sciences.

About Nihon Medi-Physics Co. Ltd.

Nihon Medi-Physics Co. Ltd. is a leading radiopharmaceutical company in Japan. Nihon Medi-Physics Co., Ltd. engages in the research, development, manufacture, sale, and purchase of radioactive pharmaceuticals, as well as radioactive medical devices and their related products for hospitals in Japan. It offers single photon emission computed tomography (SPECT) diagnostic agents and positron emission tomography (PET) diagnostic agents that offer diagnostic information from various aspects ranging from morphological images to functional changes in blood flow and metabolism; and Iodine-125 radioactive seeds, a medical device for brachytherapy. The company was founded in 1973 and operates as a joint venture between Sumitomo Chemical Company, Limited and GE Healthcare Limited.

About FACBC

FACBC is invented by the researchers at Emory University in the United States. It is a synthetic amino acid analogue radiolabeled by F-18 and targets the amino acid transporters specifically overexpressed in tumor cells compared to normal cells. The clinical researches conducted by Emory University and other medical institution worldwide have shown that FACBC has tumor uptake comparable to FDG with a much lower background signal in the brain and pelvic area. Moreover, FACBC shows lower uptake in inflammatory tissues compared to FDG. NMP has been granted world-wide exclusive rights from Emory University to make, use, and sell FACBC as a diagnostic imaging agent. NMP has granted Blue Earth Diagnostics exclusive rights to FACBC in western countries, and Blue Earth Diagnostics has obtained approvals from US FDA and EU EMA to market FACBC as a diagnostic agent for recurrent prostate cancer.